InsiderTrades.com logo
Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis
From Weiss Ratings   |   Ad
Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …
Find out details on these three critical Nvidia partners immediately.

Aron English Biography and Net Worth

Insider of Anebulo Pharmaceuticals
  • LinkedIn
  • Phone
  • Email
  • Website


Aron R. English has been a member of our board of directors since June 2020. He is the founder and has served as the President and Portfolio Manager of 22NW, LP, a Seattle-based value fund specializing in small and microcap investments with a multi-year investment horizon, since August 2014. Previously, Mr. English served as the director of research at Meson Capital Partners LLC, an investment firm, from January 2014 to August 2014. Prior to that, he served as director of research at RBF Capital, LLC, a provider of wealth management and financial services, from September 2010 until December 2013, after initially serving as a research analyst at the firm from September 2008 to September 2010. Mr. English served as a research assistant at McAdams Wright Ragen Inc., an investment firm, from March 2006 until September 2008. Mr. English earned his B.A. degree in English Literature with honors from the University of Washington, and holds the Chartered Financial Analyst (CFA) designation.

What is Aron R. English's net worth?

The estimated net worth of Aron R. English is at least $26.29 million as of December 23rd, 2024. Mr. English owns 15,467,300 shares of Anebulo Pharmaceuticals stock worth more than $26,294,410 as of December 29th. This net worth evaluation does not reflect any other investments that Mr. English may own. Learn More about Aron R. English's net worth.

How do I contact Aron R. English?

The corporate mailing address for Mr. English and other Anebulo Pharmaceuticals executives is , , . Anebulo Pharmaceuticals can also be reached via phone at 512-598-0931 and via email at [email protected]. Learn More on Aron R. English's contact information.

Has Aron R. English been buying or selling shares of Anebulo Pharmaceuticals?

During the past quarter, Aron R. English has bought $9,999,999.90 in shares of Anebulo Pharmaceuticals stock. Most recently, on Monday, December 23rd, Aron R. English bought 10,101,010 shares of Anebulo Pharmaceuticals stock. The stock was acquired at an average cost of $0.99 per share, with a total value of $9,999,999.90. Following the completion of the transaction, the director now directly owns 15,467,300 shares of the company's stock, valued at $15,312,627. Learn More on Aron R. English's trading history.

Are insiders buying or selling shares of Anebulo Pharmaceuticals?

During the last twelve months, Anebulo Pharmaceuticals insiders bought shares 1 times. They purchased a total of 10,101,010 shares worth more than $9,999,999.90. The most recent insider tranaction occured on December, 23rd when Director Aron R English bought 10,101,010 shares worth more than $9,999,999.90. Insiders at Anebulo Pharmaceuticals own 85.9% of the company. Learn More about insider trades at Anebulo Pharmaceuticals.

Information on this page was last updated on 12/23/2024.

Aron R. English Insider Trading History at Anebulo Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/23/2024Buy10,101,010$0.99$9,999,999.9015,467,300View SEC Filing Icon  
12/17/2021Buy400$6.59$2,636.00View SEC Filing Icon  
12/14/2021Buy412$5.89$2,426.68View SEC Filing Icon  
12/2/2021Buy13,836$5.30$73,330.80View SEC Filing Icon  
See Full Table

Aron R. English Buying and Selling Activity at Anebulo Pharmaceuticals

This chart shows Aron R English's buying and selling at Anebulo Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Anebulo Pharmaceuticals Company Overview

Anebulo Pharmaceuticals logo
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.
Read More

Today's Range

Now: $1.70
Low: $1.63
High: $1.85

50 Day Range

MA: $1.57
Low: $0.99
High: $1.90

2 Week Range

Now: $1.70
Low: $0.80
High: $3.30

Volume

90,542 shs

Average Volume

10,916 shs

Market Capitalization

$44.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis
From Weiss Ratings   |   Ad
Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …
Find out details on these three critical Nvidia partners immediately.